DBV Technologies S.A. American Depositary Shares (DBVT)

FairStock Score: 20/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable earnings power, honest accounting, and a price that leaves a margin of safety. DBV Technologies does not fit that mold. It is a clinical-stage biopharmaceutical company with two main pipeline products, Viaskin Peanut and Viaskin Milk, and 170 employees. The filed figures show tiny revenue against heavy losses: in fiscal Q2 2026, the quarter ended June 30, 2026, revenue was $700,000 and net income was -$50.4M. In fiscal Q1 2026, the quarter ended March 31, 2026, revenue was $900,000 and net income was -$47.6M. For full-year fiscal 2025, the year ended December 31, 2025, revenue was $5.6M and net income was -$146.9M; fiscal 2024, the year ended December 31, 2024, had revenue of $4.2M and net income of -$113.9M. Trailing free cash flow was -$170.6M, a negative 14.8% FCF yield on the $1.2B market cap at the 2026-10-13 close. The balance sheet has low debt, with D/E of 0.05, but returns are dreadful: ROE -142.68% and ROCE -60.60%. FairStock gives it a Piotroski score of 0/9 and a 20/100 score. At $9.03, P/B is 3.33 and P/E is negative, so there is no Graham-style earnings bargain. The Lynch category says TURNAROUND - loss in the latest year after earlier profits - but turnarounds need cash and execution. Without approved products or positive cash flow, the moat is speculative and the valuation depends on pipeline hope, not present earnings.

In plain English: DBV Technologies is a small healthcare company developing skin-patch treatments for peanut and milk allergies. The business looks weak today: it brings in very little revenue and loses large amounts of money each quarter. At the recent price of $9.03, the shares look expensive relative to those numbers, even after falling near their 52-week low.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer